Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2014

View Archived Issues

Agilis and Intrexon collaborate on DNA-based therapeutics for Friedreich's ataxia

Oprozomib shows antitumor activity in phase I/II trials in patients with hematologic malignancies

TD-6450 demonstrates improved potency against genotype 1a-resistant mutants

Karyopharm presents results from phase I study of selinexor in hematological cancers

Meiji Seika Pharma begins phase II study of ME-1111

ASTX-727 demonstrates promising preclinical pharmacokinetic profile

ProNAi Therapeutics presents promising phase II data for PNT-2258

Japanese researchers prepare new agents for diabetes and other metabolic disorders

Janssen R&D Ireland patents novel agents for RSV infection

Novel neprilysin inhibitor prodrugs disclosed by Theravance

Georgia State University divulges novel agents for bacterial infections

Cerenis reports topline data for CER-001

Eisai launches Fycompa for partial-onset seizures in patients with epilepsy

IRM synthesizes novel EGFR inhibitors for cancer

NPS Pharmaceuticals begins registration study of teduglutide in pediatric patients

Horizon-labeled Vimovo now available in the U.S.

Incyte presents interim phase II results for INCB-039110 in patients with primary myelofibrosis

Marina Biotech and Mirna Therapeutics amend agreement for microRNA therapeutics

GlaxoSmithKline presents early clinical data for afuresertib

Sanofi presents phase II data for SAR-3419 and rituximab combination in B-cell lymphoma

Probiodrug transfers CDK9 inhibitor program to AstraZeneca

Salix Pharmaceuticals completes acquisition of Santarus

Enrollment open in phase IIa study of THR-18 in stroke patients treated with tPA

Sanofi expands access to data from clinical trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...